203445-32-3

Upstream product

• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 346617-98-9 1,1-dimethylethyl 4-[(4-iodophenyl)oxy]-1-piperidinecarboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 540-38-5 p-Iodophenol 
• 203445-38-9 4-[4-(benzo[1,3]dioxol-5-ylsulfanyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 203445-13-0 4-[4-(benzo[1,3]dioxole-5-sulfonyl)-phenoxy]-[1,4']bipiperidinyl 
• 203444-54-6 4-[4-(benzo[1,3]dioxol-5-ylsulfanyl)-phenoxy]-[1,4']bipiperidinyl-1'-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

ETHER MUSCARINIC ANTAGONISTS

1,4 Di-substituted piperidine muscarinic antagonists of formula (I) or an isomer, pharmaceutically acceptable salt, ester or solvate thereof, wherein X is a bond, -O-, -S-, -SO-, -SO2-, -CO-, -C(OR)2-, -CH2-O-, -O-CH2-, -CH=CH-, -CH2-, -CH(C1-C6 alkyl)

Design and synthesis of ether analogues as potent and selective M2 muscarinic receptor antagonists

Novel, selective M2 muscarinic antagonists, which replace the metabolically labile styrenyl moiety of the prototypical M2 antagonist 1 with an ether linkage, were synthesized. A detailed SAR study in this class of compounds has yielded highly active compounds that showed M2 Ki values of 100-fold selectivity against M1, M3, and M5 receptors.